Subsequently, we investigated whether PDIA5 could predict glioma patients’ responses to checkpoint inhibitor immunotherapy in anti-CTLA-4 and anti-PD-1 based on CGGA and TCGA datasets, and found that compared with low PDIA5 group, high PDIA5 group was expected to respond better to immunotherapies (Figure 7C). This evidence concerns the gene PDIA5 and glioma.